慢性腎臟病（CKD）患者腎功能減退，引發(fā)鈣磷的代謝紊亂，進(jìn)一步導(dǎo)致各種疾病的發(fā)生。高磷血癥可能會升高CKD患者的發(fā)病率和死亡率。因而，有效控制血清磷的水平將是CKD患者預(yù)后的關(guān)鍵。傳統(tǒng)磷結(jié)合劑常含鈣、鋁成分，雖能有效降低血清磷，但不良反應(yīng)較多。綜述上市的和臨床研究中的新型磷結(jié)合劑如司維拉姆、碳酸鑭、考來替蘭和檸檬酸鐵等，其不含鈣、鋁，能有效控制血清磷水平，卻不升高血鈣，為控制高磷血癥和減少血管鈣化風(fēng)險提供了治療前景。

Chronic kidney disease (CKD) can make kidney function worsen, which causes the metabolic disorders of calcium and phosphorus, and further lead to various diseases. Hyperphosphatemia may elevate the morbidity and mortality of CKD patients. Therefore, it is important to effectively control serum phosphorus level for CKD patients. The traditional phosphate binders mostly contain calcium and aluminum, which can effectively reduce serum phosphorus, but have more adverse reactions. New phosphate binders, such as sevelamer, lanthanum carbonate, colestilan, ferric citrate, etc, can effectively control serum phosphorus level without elevating blood calcium level, which provides a new future in controlling hyperphosphatemia and not raising the risk of vascular calcification.